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COVID-19 VACCINATION IN THE UK AND IRELAND: ETHICS IN PRACTICE  
 






The purpose of this working paper (WP) is to explore questions of values in relation to the COVID-19 
vaccination programmes in the United Kingdom (UK) and the Republic of Ireland (RoI). It considers three 
fundamental questions:  
 
1. What values have, or should have, informed the COVID-19 vaccination programme? 
2. How did we go about, or how should we have gone about, determining priority groups for COVID-19 
vaccination? 
3. What are some of the practical issues faced when implementing this type of vaccination programme? 
 
The WP aims to provide a brief review of key policies, processes and practices that arose in relation to the 
design and implementation of COVID-19 vaccination programmes in the UK and the RoI. This will enable 
workshop participants to consider the three key questions noted above.  
 
By way of background, we also provide short chronologies setting out key developments in relation to COVID-
19 vaccination in the UK and RoI in Appendices A and B to this WP. As far as possible, we have endeavoured 
to ensure that the research and data presented in the WP is current as at 1 June 2021. 
 
We first present a brief overview of general developments in relation to COVID-19 vaccine development and 
rollout to date on both a local and global basis. We then proceed with an examination of key developments 
in these areas in the UK and the RoI, followed by identification of commonalities and differences as between 
the two. In the final section, we consider the broader issue of values raised by the COVID-19 vaccination 
programmes in the UK and the RoI. 
 
 
PART I: COVID-19 VACCINE DEVELOPMENT AND ADMINISTRATION  
 
On 31 December 2019, the World Health Organization (WHO) was notified of several cases of pneumonia of 
unknown origin in the city of Wuhan, China.2 It soon became apparent that a new coronavirus was implicated, 
which would soon become known as SARS-CoV-2. Within a few weeks, cases of human-to-human 
transmission were increasing exponentially within and across borders. At the end of January 2020, the WHO 
declared a Public Health Emergency of International Concern (PHEIC) pursuant to the International Health 
Regulations.3 In March 2020, the WHO declared COVID-19 to be a global pandemic.4 As at the time of writing 
(8 June 2021), there are over 174 million cases of COVID-19 worldwide noted, and more than 3.7 million 
deaths from the disease recorded. 
 
                                                 
2 World Health Organization, ‘Pneumonia of Unknown Cause – China, 5 January 2020. 
https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/  
3 World Health Organization, International Health Regulations 2005 (3rd edition, 2016). 
https://www.who.int/ihr/publications/9789241580496/en/ 
4 World Health Organization, ‘WHO Director-General's Opening Remarks at the Media Briefing on COVID-19, 11 March 
2020’ https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-
covid-19---11-march-2020 
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Thus, the demand for a vaccine as a response to a global health challenge has never been more acute. As 
Calina et al. note ‘[t]he most favorable epidemic control scenario, which provides long-term protection 
against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine.’5 
 
In early 2020, over 100 vaccine projects were reported.6 As of 1 June 2021, there are a total of 287 candidate 
vaccines, with 102 in clinical phase and 185 in pre-clinical phase.7 Despite the unprecedented rapid 
development of multiple vaccines, demand continues to overtake supply.8 Recognising the significant 
healthcare inequalities which exist globally, and which have arguably been amplified by the pandemic, in 
May 2020, the WHO initiated a Solidarity Call to Action for COVID-19 with the goal of realising ‘equitable 
global access to COVID-19 health technologies through pooling of knowledge, intellectual property and 
data.’9  
 
Vaccination allocation and immunisation prioritisation are therefore key considerations. This section of the 
working paper (WP) considers the values which informed the rollout of the COVID-19 vaccination first in the 
UK and then in the Republic of Ireland. 
 
 




In the UK, the first cases of COVID-19 were reported at the end of January, with the first case of a person 
contracting COVID-19 within the UK occurred at the end of February.10 Initially, the UK government and their 
scientific advisors appeared to support a ‘herd immunity’ approach to managing the disease,11 but this had 
changed by mid-March, with pandemic modelling suggesting that following such an approach would soon 
overwhelm the National Health Service (NHS).12 A series of lockdown measures were subsequently imposed 
to restrict people’s movements, including the use of social distancing, working from home and only 
undertaking essential travel, leading to the cancellation of large social and sporting events.13 The UK 
Parliament subsequently adopted a piece of emergency legislation known as the Coronavirus Act 2020 to 
enable a UK-wide approach to manage lockdown measures, as well as a myriad of other issues that had arisen 
in the wake of the pandemic.14  
 
                                                 
5 D Calina and others, ‘COVID-19 Vaccines: Ethical Framework Concerning Human Challenge Studies’ (2020) 28(2) 
Journal of Pharmaceutical Sciences 807. 
6 J Corum, K Sheikh, and C Zimmer, ‘Different Approaches to a Coronavirus Vaccine’, The New York Times, 20 May 
2020.  
7 World Health Organization, ‘COVID-19 Tracker and Landscape’  https://www.who.int/publications/m/item/draft-
landscape-of-covid-19-candidate-vaccines 
8 For further discussion on global equitable access to COVID-19 vaccines please see, A McMahon, ‘Global Equitable 
Access to Vaccines, Medicines and Diagnostics for COVID-19: The Role of Patents as Private Governance’ (2021) 47 J 
Med Ethics 142. 
9 World Health Organization, ‘Solidarity Call to Action’, 29 May 2021 https://www.who.int/initiatives/covid-19-
technology-access-pool/solidarity-call-to-action  
10 BBC News. ‘Coronavirus: Latest Patient was First to Be Infected in UK’, BBC News, 29 February 2020. 
https://www.bbc.com/news/uk-51683428  
11 D Conn and P Lewis, ‘Documents Contradict UK Government Stance on Covid-19 ‘Herd Immunity’, The Guardian, 12 
April 2020 https://www.theguardian.com/world/2020/apr/12/documents-contradict-uk-government-stance-on-
covid-19-herd-immunity 
12 N Ferguson et al, Imperial College Covid-19 Response Team, ‘Report 9: Impact of Non-Pharmaceutical Interventions 
(NPIs) to Reduce COVID-19 Mortality and Healthcare Demand’ Spiral https://doi.org/10.25561/77482. 
13 B Doherty, ‘The Exit Strategy: How Countries Around the World are Preparing for Life after Covid-19’ The Guardian, 
18 April 2020. https://www.theguardian.com/world/2020/apr/19/the-exit-strategy-how-countries-around-the-world-
are-preparing-for-life-after-covid-19 
14 Coronavirus Act 2020, UK Public General Acts 2020, c 7. 
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ii. COVID-19 morbidity and mortality data  
 
By way of background, there is a standardised approach to the reporting of deaths at the global level. This is 
set out under ‘cause of death’ in the WHO’s International Classification of Diseases guidelines. Most routine 
mortality collected in the UK is based on what the WHO describes as the ‘underlying cause of death’. This is 
defined as ‘a) the disease or injury which initiated the train of morbid events leading directly to death, or b) 
the circumstances of the accident or violence which produced the fatal injury.’15 Death registration data is 
collected by the General Register Office in England & Wales. This is passed to the Office of National Statistics 
(ONS), which in turn publishes a range of mortality statistical data and is responsible for passing on a range 
of other government departments, as well as the WHO.  
 
Notwithstanding this standardised approach, the COVID-19 pandemic has revealed that individual countries 
(including the UK) have taken their own approach to reporting causes of death in line with national guidelines. 
This may encompass the above classifications, but also be subject to further limitations imposed by an 
individual country. For example, the UK government and devolved nations record COVID-19 deaths as being 
based on a COVID-19 positive test within 28 days of death.16 
 
Successive waves of the COVID-19 pandemic in the UK in the past year have resulted in significant morbidity 
and mortality in the UK from the disease. In January 2021, the UK reached the grim milestone of 100,000 
Covid-19 related deaths in the UK, against a background where the country had the highest death rate per 
capita in the world for the pandemic at the time.17  
 
As at 1 June 2021, there have been 4,490,438 cases of COVID-19 infection recorded in the UK, with over 
127,782 deaths. These numbers are significant, and behind the sterility of the numerical data lie stories of 
separation, anguish and loss.  
 
iii. COVID-19 vaccines and regulatory approval  
 
A number of COVID-19 vaccines have been authorised by the UK regulator, the Medicines and Healthcare 
Regulatory Authority (MHRA). On 2 December 2020, the MHRA approved the Pfizer/BioNTech vaccine, which 
is an mRNA vaccine. At the time the vaccine was approved, the optimal approach to administration of this 
vaccine was considered to involve two injections being administered at least two days apart.18 The vaccine 
was to be stored in a freezer at -80 °C to -60°C and needed to be administered within six hours of thawing.19  
 
The Pfizer/BioNTech vaccine was approved by the MHRA under Regulation 174 of the Human Medicine 
Regulations 2012 (2012 Regulations). In regulatory terms, the MHRA were able to authorise the rapid 
temporary approval of the vaccine, due to the serious public health concerns pertaining to the COVID-19 
pandemic. The temporary authorisation allowed for the vaccine to be used by people over the age of 16 to 
prevent COVID-19, but it did not allow for a marketing authorisation.20  
 
                                                 
15 World Health Organization, ‘International Statistical Classification of Diseases and Related Health Problems’ (ICD-10, 
5th edn, WHO, 2016) https://icd.who.int/browse10/2016/en  
16 UK Government, UK Coronavirus Dashboard. https://coronavirus.data.gov.uk/ 
17 BBC News, ‘Covid Deaths: “Hard to Compute Sorrow” of 100,000 milestone – PM’, 26 January 2021. 
https://www.bbc.co.uk/news/uk-55814751 
18 Medicines and Healthcare Products Regulatory Agency (MHRA), ‘Information for Healthcare Professionals on 
Pfizer/BioNTch COVID-19 Vaccine’, 4 June 2021. https://www.gov.uk/government/publications/regulatory-approval-of-
pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine 
19 Ibid.  
20 Medicines and Healthcare Products Regulatory Agency (MHRA, ‘Decision: Information for UK Recipients on 
Pfizer/BioNTech COVID-19 Vaccine’, 4 June 2021. https://www.gov.uk/government/publications/regulatory-approval-
of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine 
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On 30 December 2020, the AstraZeneca (AZ) vaccine received regulatory approval by the MHRA for people 
over the age of 18 in the UK. The AZ vaccine was also approved under the 2012 Regulations. The AZ vaccine 
is a viral vector type vaccine and, therefore, differs from the mRNA approach adopted by Pfizer. It can be 
stored at 2°C-8°C in a standard fridge, making it much more accessible and straightforward in terms of 
delivery.21 It involves two injections, ideally to be administered between four and 12 weeks of receiving the 
first injection.  
 
On 8 January 2020, the Moderna vaccine, another mRNA vaccine, was approved by the MHRA under the 
same 2012 Regulations. Like the Pfizer/BioNTech vaccine, the Moderna vaccine is another mRNA vaccine. 
The package leaflet gives the following explanation: The Moderna vaccine works by causing the body to 
produce protection (antibodies) against the virus that causes COVID-19. It uses a substance called messenger 
ribonucleic acid (mRNA) to carry instructions that cells in the body can use to make the spike protein that is 
also on the virus. The cells then make antibodies against the spike protein to help fight off the virus.22 It is 
stored at -20°C and involves the administration of two doses for people in the UK over the age of 18 and, 
following consultation with healthcare professionals, the vaccine can be taken by pregnant people and those 
who are breastfeeding.23  
 
The MHRA recommended administrating the Pfizer and AZ vaccines at different intervals to those initially 
advised by the pharmaceutical companies. A three-week gap between doses was originally scheduled for the 
Pfizer vaccine, but the UK decided to delay the gap between doses to ensure that as many people as possible 
received one vaccine and, thus, some protection from COVID-19.  
 
Recently published data showed that this strategy may have proved effective. Public Health England and the 
University of Birmingham indicates that a 12 week gap between doses of the Pfizer vaccine ‘increased the 
peak SARS-CoV-2 spike specific antibody response 3.5-fold compared to those who had the second vaccine 
at three weeks’ and ‘extending administration of the second Pfizer vaccine to 12 weeks potentially enhances 
and extends antibody immunity’.24 There is also research to indicate that the 12 week gap between doses of 
the AZ vaccine has also had a positive effect on efficacy.25 
 
The Janssen (Johnson & Johnson) vaccine, which is a viral vector vaccine, was granted Conditional Marketing 
Authorisation (CMA) by the MHRA on 28 May 2021. Unlike the other COVID-19 vaccines, only one dose is 
required for this vaccine. It can be stored in the refrigerator between 2°C-8°C.  
 
It was approved under the European Commission Decision Reliance Route.26 The decision of European 
Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is relied upon. The decision 
of the CHMP is considered by the MHRA when deciding upon the quality, safety and effectiveness of the 
actual vaccine.27 The decision of the MHRA has been endorsed by the Independent Commission on Human 
                                                 
21 Medicines and Healthcare Products Regulatory Agency (MHRA), ‘Oxford University/AstraZenecaCOVID-19 Vaccine 
Approval’, 30 December 2020. https://www.gov.uk/government/news/oxford-universityastrazeneca-covid-19-
vaccine-approved 
22 ‘Package Leaflet: Information for the User COVID-19 Vaccine Moderna Dispersion for Injection’, revised 03/2021. 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975784/PIL_Mo
derna_01.04.2021.pdf (accessed 14 May 2021).  
23 MHRA, ‘Moderna Vaccine Becomes Third COVID-19 Vaccine Approved by UK Regulator’, 08 January 2021. 
 https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator  
24 University of Birmingham, ‘Delaying Second Pfizer Vaccine to 12 Weeks Significantly Increases Antibody Responses 
in Older People Finds Study’, 14 May 2021.  https://www.birmingham.ac.uk/news/latest/2021/05/covid-pfizer-
vaccination-interval-antibody-response.aspx  
25 J Wise, ‘Covid-19: New Data on Oxford AstraZeneca Vaccine Backs 12 week Dose Intervals’ (2021) 372 BMJ n326. 
https://www.bmj.com/content/372/bmj.n326  
26 ‘European Commission (EC) Decision Reliance Procedure’  https://www.gov.uk/guidance/european-commission-ec-
decision-reliance-procedure  
27 UK Government, ‘Regulatory Approval of COVID-19 Vaccine Janssen’, 28 May 2021. 
https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen 
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Medicines. In NI, the Janssen vaccine was authorised under the CMA that was granted by the EMA on 11 
March 2021.  
iv. COVID-19 vaccination and priority groups 
 
The Joint Committee on Vaccination and Immunisation (JCVI) is the UK’s national scientific advisory body on 
vaccinations and their recommendations apply throughout the UK. On 30 December 2020, the JCVI approved 
an initial priority list for vaccination, which has been updated over time.28 The list has been adopted by the 
UK and the devolved administrations. Details of the JCVI’s current priority list for vaccination is set out in 
Appendix D.  
 
v. COVID-19 vaccination and side effects  
 
On 7 April 2021, the MHRA stated that the benefits of receiving the AZ vaccine (and protecting people from 
contacting COVID-19) outweighed the concerns pertaining to possible blood clots post inoculation.29 The 
advice followed the temporary suspension of AZ vaccine in a number of European countries. On 28 April 
2021, 242 blood clots had been reported to the MHRA following the administration of the AZ vaccine.30 
However, on 7 May 2021, the JCVI informed the UK government that, on a precautionary basis, the AZ vaccine 
ought not to be administered to anyone under the age of 40 if another vaccine were available and if no 
significant delay were caused.31  
 
vi. COVID-19 vaccination programme rollout 
 
On 20 December 2020, it was announced by Matt Hancock that there were plans to create vaccine centres 
in the UK. Thus, vaccines would be administered in designated centres as well as in hospitals, care homes 
and by General Practitioners (GPs).32  
 
On 08 December, a 90-year-old, Margaret Keenan, from Enniskillen in County Fermanagh, was the first 
patient outside of the clinical trials to receive the vaccine by the NHS. She received her second dose on 29 
December 2020. On 14 December, the first Pfizer vaccines were administered in Scottish care homes. On 15 
December, over 70 vaccination centres were opened in England. Care home vaccine centre locations opened 
on 16 December in England, where larger care homes were initially priorities. GPs started to provided 
vaccines later that week in December. In the UK, vaccines are also administered in community pharmacies. 
Patients in England started to receive the AZ vaccine on 04 January. The first four priority groups were given 
their vaccines during this initial stage, in line with the vaccination strategy. By 14 February, these priority 
groups had all been given their first dose. The Moderna vaccine was first administered on 7 April 2021 and 
the rollout began on 13 April. Around this time, new advice from the MHRA indicated that AZ should not be 
given to people under 30. This had an adverse impact on the vaccination rollout and new strategies were 
adopted. It was announced by Patricia Donnelly, Head of Covid-19 NI Vaccine Programme that, in areas where 
there was a low uptake of vaccinations in NI, pop-up centres would be opened.33  
 
By the end of April 2021, the vaccination rollout had opened up to those aged over 40 in England and those 
aged 30-34 in NI. On 07 May 2021, it was decided that those under 40 should not receive the AZ vaccine, 
                                                 
28 Department of Health, ‘COVID-19 Vaccination Programme Phased Plan’, 8 March 2021 https://www.health-
ni.gov.uk/sites/default/files/publications/health/covid-vacc-prog-update-plan.pdf 
29 ‘UK Regulator Confirms that People Should Continue to Receive the COVID-19 Vaccine AstraZeneca’, 7 April 2021. 
https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-
vaccine-astrazeneca 
30 Ibid.  
31 Public Health England, ‘JCVI Ddvises on COVID-19 Vaccine for People Aged Under 40’, 7 May 2021. 
 https://www.gov.uk/government/news/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40  
32 BBC News, ‘Covid-19: UK Setting Up for Vaccine Centres Ready for Rollout – Matt Hancock’. 
https://www.bbc.com/news/uk-55021334 
33 L Cullen, ‘Covid-19: Pop Up Clinics to Target Areas of Vaccine Low Uptake’, BBC News, 21 April 2021. 
https://www.bbc.com/news/uk-northern-ireland-56837747 
Electronic copy available at: https://ssrn.com/abstract=3887603
University of Edinburgh School of Law Working Paper No 2020/16 
 
Page 10 of 38 
again having an impact on the practicalities pertaining to the rollout. As things stand, in England, anyone 
aged 25 or over can book a vaccine, in Scotland, people over 30 can get a vaccine, while in Wales and NI, 
anyone over the age of 18 is eligible for a vaccine. This is at a time when the NHS is in a state of crisis. It is no 
overstatement to say that the vaccination programme has been a success story.  
 
As at 1 June 2021, 39,585,665 first doses of COVID-19 vaccines have been administered in the UK, as well as 
26,073,284 second doses.34 Further details of the rates of COVID-19 vaccination on a UK-wide basis, as well 
as across the UK’s four nations are set out in Appendix E.  
 
vii. COVID-19 vaccination and consent issues 
 
Unlike the RoI, consent has not presented itself as a key issue. This is largely due to the well-established 
framework that exists (such as the Mental Capacity Act 2005 in England and Wales).  
 
viii. COVID-19 vaccine hesitancy  
 
The issue of vaccine hesitancy is complex, and it is apparent that some of the hesitancy is imposed on people. 
It derives from a number of factors, some of which have been identified by the Nuffield Council on Bioethics 
and include benefits versus risks/uncertainty, mis-information (including information provided by influencers 
on social media), trust, values and practical condensations (e.g., childcare duties, availability, changing 
address, transport costs etc.)35 The Nuffield Council has identified a number of potential strategies to reduce 
vaccine hesitancy. These include education and information campaigns, community engagement and 
incentivised and compulsory vaccination.36 The primary lesson, however, is that, notwithstanding this 
hesitancy, the UK, in general, has a very high vaccine uptake, with, for example, 95% of the over 50s 
population taking the vaccine.37  
 
There are a number of surveys which indicate that people from some ethnic minorities are somewhat 
hesitant to take up their COVID-19 vaccine offer.38 There is historical data to suggest that there is a lower 
vaccine uptake in areas that have a higher population of ethnic minority people.39 According to Office of 
National Statistics, the main reason for vaccine hesitancy relates to perception about side effects and the 
potential impact of the vaccine on future health and wellbeing. According to Robertson et al, trust in the 
vaccine among black respondents is another significant reason for vaccine hesitancy.40 Razai et al state that 
‘[t]rust is eroded by systemic racism and discrimination, previous unethical healthcare research in black 
populations, under-representation of minorities in health research and vaccine trials, and negative 
experiences within a culturally insensitive healthcare system’.41 They also argue that barriers in terms of 
access exist (e.g., vaccine location and time). According to the Nuffield Council on Bioethics: 
                                                 
34 Department of Health, ‘NI Covid-19 Vaccinations Dashboard’  https://covid-19.hscni.net/ni-covid-19-vaccinations-
dashboard/  
35 MS Razai, T Osama and D G J McKechnie, ‘COVID-19 Hesitancy Among Ethnic Minority Groups’ (2021) 372n BMJ 
513. https://www.bmj.com/content/372/bmj.n513 
36 Nuffield Council on Bioethics, ‘Vaccine Access and Uptake’ https://www.nuffieldbioethics.org/publications/vaccine-
access-and-uptake 
37 BBC New, ‘Covid: Vaccine Uptake Among Over 50s Hits 95% in England’, BBC News, 22 April 2021. 
https://www.bbc.com/news/health-56849874 
38 Office of National Statistics, ‘Coronavirus and the Social Impacts on Great Britain: 29 January 2021’ 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/bulletins/corona
virusandthesocialimpactsongreatbritain/29january2021; Royal Society for Public Health, ‘New Poll Finds Ethnic 
Minority Groups Less Likely to Want Covid Vaccine’ https://www.rsph.org.uk/about-us/news/new-poll-finds-bame-
groups-less-likely-to-want-covid-vaccine.html  
39 Public Health England, ‘Seasonal Influenza Vaccine Uptake in Children of Primary School Age’, PHE, 2000-20; Razia et 
al (n 35).  
40 E Robertson et al, ‘Predictors of COVID-19 Vaccine Hesitancy in the UK Household Longitudinal Study’ (2021) 94, 
Brain, Behaviour, and Immunity 41-50.   
41 Razai et al (n 35).  
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Vaccine hesitancy among people from some minority ethnic backgrounds during the roll out of 
COVID-19 vaccines has been linked to a lack of trust resulting from systemic racism and 
discrimination, historical abuses such as the Tuskegee syphilis study, underrepresentation of 
minorities in vaccine research, and negative experiences in the healthcare system.42 
 
Razai et al argue that, amongst some healthcare workers, there has been some vaccine hesitancy, and this 
‘is an area of concern because [their]… roles as trusted sources of health information, and because of their 
greater personal exposure to infections in a healthcare setting’.43 There has also been some hesitancy on the 
parts of pregnant women as well as women who may wish to become pregnant (i.e. women of child bearing 
age) which may result from disinformation and the fact that pregnant women were not included in the clinical 
trials.44  
 
ix. COVID-19 vaccine passports and immunisation certificates  
 
As the rollout of the UK COVID-19 vaccination programme has progressed, questions have been raised about 
whether individuals should hold vaccine passports or other forms of certification to show that they have been 
vaccinated. It has been suggested that this could be useful for the purposes of international travel, as well as 
entry into hospitality settings.45 The UK government engaged in a public consulting on the feasibility of 
vaccine passports from 15 March to 29 March 2021.46  
 
On 17 May 2021, NHS England introduced a COVID passport on the NHS England app. This app contains NHS 
records and there is a section on vaccination status. In order to use the app, there is a need to be over the 
age of 13 and to be registered with a GP. As things stand, no such app exists elsewhere in the UK, but the UK 
government has indicated that it is working with the administrations in NI, Scotland and Wales in relation to 
creating similar apps.47  
 
In the UK, a traffic light system is in operation. If a country is in the red list, before travelling, passengers must 
take a COVID-19 test and book a hotel quarantine package, which includes another two tests. They must also 
fill-in in a passenger locator form. Once travellers arrive in the UK, they need to quarantine in the hotel and 
take two tests. Anyone travelling to a country on the amber list must complete a COVID-19 test as well as 
book and pay for day 2 and day 8 travel tests and complete a passenger locator form. On return to the UK, a 
COVID-19 test must be taken on days 2 and 8 and travellers to the country must quarantine at home (or 
where they are staying) for 10 days. If a country is on the green list, before travel, passengers need to take a 
COVID-19 test, book and pay for day 2 and day 8 travel tests and complete a passenger locator form. On 
return to the UK, a COVID-19 test must be taken on days 2 and 8, but there is no need to quarantine for 10 
days.  
 
More recently, the European Commission has recommended that people who have been vaccinated with a 
European Union (EU) approved vaccine at least two weeks before travelling should be permitted to travel 
                                                 
42 Nuffield Council on Bioethics (n 36). 
43 Razia et al (n 35).  
44 L Osborne-Crowley, ‘“There is a Lot of Distrust’: Why Women in their 30s are Hesitant about the COVID Vaccine’ The 
Guardian, 30 January 2021. https://www.theguardian.com/society/2021/jan/31/there-is-a-lot-of-distrust-why-
women-in-their-30s-are-hesitant-about-the-covid-vaccine  
45 Institute for Government, Vaccine Passports, https://www.instituteforgovernment.org.uk/explainers/vaccine-
passports 
46 UK Government, Cabinet Office, ‘COVID-status Certificate Review – Call for Evidence – Now Closed, 15 March 2021. 
https://www.gov.uk/government/consultations/covid-status-certification-review-call-for-evidence  
47 BBC News, ‘What is a Covid Passport and What are the Plans for the NHS App?’ 12 May 2021. 
https://www.bbc.com/news/explainers-55718553 
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within the EU.48 The Commission has also proposed that the EU certificate would include non-EU countries.49 
This would be evidenced by way of a ‘digital green certificate’. At the time of writing, it is unclear as to exactly 
how well this will work in practice.  
 
x. COVID-19 vaccine injury and redress  
 
Under the Vaccine Damage Payments Act 1979, if an individual in the UK is left with severe disabilities 
following the administration of a vaccine, a tax-free payment of £120,000 may be provided. This is called the 
‘vaccine damage payment’.50 Severe disability means that the person must be at least 60 % disabled, which 
includes both mental and physical disability. COVID-19 is now included in the list of diseases to which the 
Vaccine Damage Payments Act 1979 applies.51  
 
 




In the RoI, the first cases of COVID-19 were reported at the end of February,52 with sadly, the first death of a 
person from COVID-19 in the RoI reported on 11th March 2020.53 In contrast to the initial approach taken in 
the UK, a containment and preventionist approach was adopted in the RoI, with a series of lockdown 
measures imposed to restrict people’s movements at an early stage in the pandemic.54 These measures 
included the use of social distancing, the closure of childcare facilities, schools and higher education 
institutions, the implementation of remote working, and only undertaking essential travel, leading to the 
cancellation of large social and sporting events. The Irish Government subsequently adopted two pieces of 
emergency legislation: the Health (Preservation and Protection and Other Emergency Measures in the Public 
Interest) Act 2020 and the Emergency Measures in the Public Interest (Covid 19) Act 2020 to enable lockdown 
measures, as well as other issues which had arisen as a result of the pandemic.55  
 
ii. COVID-19 morbidity and mortality data  
 
As previously noted, there is a standardised approach to the reporting of deaths at the global level. This is 
set out under ‘cause of death’ in the WHO’s International Classification of Diseases guidelines. This is the 
approach followed in the RoI, and in this jurisdiction, morbidity and mortality data is collected by the Health 
Protection Surveillance Centre (HPSC).56 In line with the WHO methodology, the definition of a COVID-19 
death adopted by the HPSC provides that ‘[f]or surveillance purposes, COVID-19 deaths include deaths in all 
possible, probable and confirmed COVID-19 cases (as per the COVID-19 case definition and all should be 
notified, unless there is a clear alternative cause of death that cannot be related to COVID-19 (e.g. trauma). 
There should be no period of complete recovery from COVID-19 between the illness and death.  
 
All COVID-19 deaths are notified regardless of the setting, including home, community and hospital settings. 
HPSC reports all deaths among these COVID-19 cases as outlined above and does not just confine the death 
reporting to those who die within 28 days of a positive test.’ The guidance further provides that discharge 
                                                 
48 BBC News, ‘EU Unveils Plans for Overseas Tourists to Return’, 3 May 2021. https://www.bbc.com/news/world-
europe-56970398 
49 C Hymas, ‘Holidays to Europe with Covid Vaccine Passports Get Green Light’, The Guardian, 17 May 2021. 
https://www.telegraph.co.uk/news/2021/05/17/holidays-europe-covid-vaccine-passport/ 
50 NI Direct, ‘Vaccine Damage Payment’  https://www.nidirect.gov.uk/articles/vaccine-damage-payment-0  
51 Vaccine Damage Payments (Specified Disease) Order 2020. 
52 gov.ie - Statement from the National Public Health Emergency Team - Saturday 29 February (www.gov.ie) 
53 gov.ie - Statement from the National Public Health Emergency Team - Wednesday 11 March (www.gov.ie) 
54 gov.ie - Statement from the National Public Health Emergency Team - Thursday 12 March (www.gov.ie) 
55 Health (Preservation and Protection and Other Emergency Measures in the Public Interest) Act 2020. 
56 The HPSC is a specialist agency within the HSE for the surveillance of all communicable diseases. 
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from ICU or hospital is not in itself evidence of recovery, rather, this is based on clinical assessment or the 
passing of a period of over three months since the initial diagnosis. As of 1 June 2021, 255,000 cases of COVID-
19 infection and 4,941 deaths have been recorded in the RoI. 
 
iii. COVID-19 vaccines and regulatory approval  
 
For EU Member States, applications for the approval of COVID-19 vaccines are made centrally to the 
European Medicines Agency (EMA). Where the EMA is satisfied with the safety, quality, and effectiveness of 
a vaccine, it will make a recommendation to the European Commission to grant a conditional marketing 
authorisation. Once the European Commission makes a grant of approval, such is valid across all EU Member 
States, including Ireland.  
 
To-date, four vaccines have been authorised by the EMA (two mRNA vaccines and two virus vector vaccines), 
with a number remaining under rolling review. On 21 December 2020, the EMA recommended the first 
COVID-19 vaccination for authorisation in the EU, developed by Pfizer/BioNTech.57 Shortly thereafter, on 6 
January 2021, the EMA recommended Moderna for authorisation in the EU.58 On 29 January 2021, AZ is 
recommended for authorisation in the EU by the EMA,59 and on 11 March 2021, the EMA recommended 
granting conditional authorisation for Johnson & Johnson’s COVID-19 vaccine Janssen.60  
 
In the RoI, in the case of each vaccine, the National Immunisation Advisory Committee (NIAC) publish 
recommendations for use.61 Relevant materials are then prepared, and rollout plans are finalised. Some of 
the recommendations by NIAC will be discussed in more detail later in this WP, however, in summary, mRNA 
vaccines (Pfizer/BioNTech and Moderna) have been recommended for all age categories, whilst the virus 
vector vaccines (AZ and Janssen) were previously not recommended for those aged under 60.62 Additionally, 
NIAC recommended that pregnant people should be offered a mRNA COVID-19 vaccine.63 
 
iv. COVID-19 vaccination and priority groups 
 
One of the most interesting ethical issues around vaccination policies is prioritisation for immunisation. With 
the overarching ethical goals of reduction of morbidity and mortality, countries worldwide have developed 
frameworks for the prioritisation of immunisation. This purpose of this section of the WP is to provide an 
overview of the approach adopted to vaccination policies and practices in the RoI. 
 
In early June 2020, the Department of Health presented a draft proposal for the establishment of a vaccine 
taskforce to the National Public Health Emergency Team (NPHET).64 This proposal recommended that a 
                                                 
57 EMA recommends first COVID-19 vaccine for authorisation in the EU | European Medicines Agency (europa.eu) 
58 EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU | European Medicines Agency (europa.eu) 
59 EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU | European Medicines Agency 
(europa.eu) 
60 Fourth safe and effective vaccine against COVID-19 (europa.eu) 
61 The National Immunisation Advisory Committee was established in 1998 by the Royal College of Surgeons Ireland. 
It is an independent expert group with membership from immunisation from a range of healthcare professional bodies 
that provides evidence-based advice to the Chief Medical Officer and the  Department of Health on 
vaccines, immunisation, and related health matters to inform health policies in Ireland. For further detail, see 
https://www.rcpi.ie/policy-and-advocacy/national-immunisation-advisory-committee/ 
62 Originally, NIAC recommended that the virus vector vaccines AstraZeneca and Janssen be provided to the 60-69 age 
category. This advice was subsequently revised on 29 April 2021, where it recommended that those aged 50 and over 
could receive this vaccine. More recently, NIAC have advised that people in their 40s can be given a choice and where 
they decline AstraZeneca and/or Janssen, they will be offered mRNA vaccines as supplies become available. See, People 
in their 40s to be given choice of AstraZeneca or J&J vaccine (irishtimes.com) 
63 NIAC-Recommendations-re-vaccination-in-pregnancy-26.04.2021.pdf  
64 The National Public Health Emergency Team (NPHET), a body of approx. 30 health and science professionals, was 
established in January 2020 to provide advice on COVID-19, see Department of Health, National Public Health 
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COVID-19 Immunisation Strategy Group would identify priority groups for vaccination, amongst other 
objectives. On 18 June 2020, NPHET recommended that the Immunisation Strategy Group be established.65 
Parallel to this, the European Commission released the EU strategy for COVID-19 vaccines, with three core 
objectives: ‘1. Ensuring the quality, safety and efficacy of vaccines; 2. Securing timely access to vaccines for 
Member States and their population while leading the global solidarity effort; and 3. Ensuring equitable 
access for all in the EU to an affordable vaccine as early as possible.’66 
 
In the RoI, guidance on groups for immunisation prioritisation was developed and revised from November 
2020 to April 2021 by the COVID-19 Immunisation Strategy Group and NIAC, with input from the Department 
of Health, the HSE, and the Health Information and Quality Authority (HIQA). On 2 November 2020, NIAC, at 
the request of the Department of Health, assisted the COVID-19 Immunisation Strategy Group, and presented 
their interim recommendations for identifying priority groups for vaccination,67 noting the objective of the 
vaccination programme is to ‘ensure equitable access to a safe and effective vaccine with the goals of limiting 
mortality and morbidity from COVID-19, protecting healthcare capacity and enabling social and economic 
activity.’68  
 
Priority groups were identified ‘according to the current and evolving understanding of the clinical, 
microbiological and epidemiological profile of COVID-19 internationally and in Ireland, with a focus on those 
at greatest risk from COVID-19.’69 Additionally, it was noted that the foundations for the priority decisions 
made regarding the allocation of a COVID-19 vaccine are based on four core ethical principles: 1. Moral 
equality; 2. Minimisation of harm; 3. Fairness; and 4. Reciprocity.70  
 
A four-phase approach to the rollout of the vaccine was recommended, from highest to lowest priority.71 The 
criteria for prioritisation included: the risk of acquiring the disease; the risk of severe disease and death; the 
risk of a negative impact on society; and the risk of transmitting infection to others. The strategy for the 
allocation of COVID-19 vaccines was announced by the Minister for Health on 8 December 2020.72 
 
The priority list for vaccination has been revised. On 22 February 2021, NIAC published updated 
recommendations on priority groups for vaccination which advised the inclusion of additional medical 
conditions to the existing list of conditions associated with a risk of serious COVID-19 disease and death.73 
NIAC also advised that after the vaccination of those aged 70 and older, those aged 16-69 at very-high risk 
                                                 
Emergency Team – COVID-19 Meeting Note, 11 June 2020, https://www.gov.ie/en/collection/691330-national-public-
health-emergency-team-covid-19-coronavirus/ 
 
65 National Public Health Emergency Team (NPHET), Meeting Minutes, 18 June 2020. 
https://www.gov.ie/en/collection/691330-national-public-health-emergency-team-covid-19-coronavirus/ 
66 European Commission, EU Strategy for COVID-19 Vaccines (2020). https://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:52020DC0245&from=EN 
67 Priority-groups-SARS-CoV-2-vaccine-021120-.pdf  
68 https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/covid19.pdf  
69 Ibid. 
70 Ibid. 
71 Phase one included frontline healthcare workers; essential workers e.g. gardai; those at greatest risk of severe illness 
and death and their caregivers; Phase two included teachers and others who are essential to education; those in 
essential jobs and who cannot avoid a high risk of exposure; adults aged 18-64 living or working in crowded 
accommodation; and adults aged 55-64 years; Phase 3 included young adults (18-34) due to increased levels of social 
contact; and those in industries important to the functioning of society and who are at moderately high levels of 
exposure; Phase 4 included adults aged 35-54 who did not have access to the vaccine in prior phases; and children. 
72 gov.ie - Minister for Health announces the allocation strategy for COVID-19 vaccines (www.gov.ie) 
73 Conditions included cancer patients not covered under the previous cohort, cerebral palsy, and those with intellectual 
disabilities. 20210301-update-NIAC-Recommendations-for-COVID-19-Vaccine-Prioritisation.pdf 
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should be next to be vaccinated.74 These recommendations are accepted by the Minister for Health on 23 
February 2021.75  
 
More recently, on 29 March 2021, NIAC published a revised list for immunisation prioritisation, 
recommending that an ‘operationally simple, age-based programme for those aged 16-64 in descending 
order is the most equitable and efficient way of continuing the vaccination rollout.’76 This decision sparked 
considerable outcry by teachers’ unions the Garda Representative Association (GRA).77  
 
v. COVID-19 vaccination and side effects  
 
Whilst all medicines typically have side-effects, most debate in public discourse and the media has related to 
the safety of COVID-19 vaccines. Significant attention was given to the safety of the virus vector vaccines (AZ 
and Janssen) following reports of blood clots. In March 2021, an EMA safety committee commenced an 
investigation into a batch of the AZ vaccine after Austria and other Member States suspend use of the vaccine 
due to reports of blood clots.78 Ultimately, however, the committee maintained the position that the benefits 
outweigh the risks and advised that the vaccine couldcontinue to be administered.  
 
By the 16 March 2021, however, 13 EU countries including the RoI paused the use of the AZ vaccine, despite 
the EMA’s statement that the benefits outweighed the risks. Upon conclusion of the EMA’s safety committee 
determination that the benefits of the vaccine continued to outweigh the risk of side effects, NIAC 
recommended that use of the AZ vaccine resume.79 However, in subsequent guidance, the cohorts who were 
to receive this vaccine were limited. 
 
As previously noted, in the RoI, guidance surrounding the issuance of vaccines to certain age groups was 
delivered by NIAC throughout the rollout of the vaccination programme. This guidance was particularly 
pertinent in the context of ongoing concerns in relation to blood clots. On 3rd February 2021, NIAC published 
recommendations for the use of AZ in Ireland, advising that ‘any currently authorised COVID-19 vaccine can 
be given to adults of all ages, including those aged 70 and older’.80 However, NIAC ultimately recommended 
that mRNA vaccines should be used for the over 70’s ‘where practicable and timely.’81  
 
On 12 April 2021, NIAC also announced that the AZ vaccine ‘is not recommended for those aged under 60 
years, including those with medical conditions with very high or high risk of severe COVID-19 disease’,82 and 
noted that ‘mRNA vaccines are preferable for those aged under 50 years’.83 Most recently, NIAC presented 
recommendations to the Chief Medical Officer, and ultimately recommended that people in their 40s were 
to be given a choice of vaccines i.e. people who decline to accept the AZ and Johnson & Johnson vaccines will 




                                                 
74 Ibid. 
75 gov.ie - Minister Donnelly announces update to Vaccine Allocation Strategy (www.gov.ie) 
76 NIAC-Recommendations-for-Vaccine-Prioritisation-29.03.2021-update-04.01.2021-1.pdf  
77 See for example, E Loughlin and others, ‘Teachers and Gardai “Shocked and Dismayed” at Changes to Vaccine 
Rollout Plan’, Irish Examiner, 31 March 2021. 
78 COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria | 
European Medicines Agency (europa.eu) 
79 NIAC-Recommendations-re-COVID-19-Vaccine-AstraZeneca-19.03.2021.pdf  
80 NIAC-Recommendations-to-CMO-Re-AZD.pdf 
81 Ibid. 
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vi. COVID-19 vaccination programme roll-out  
 
The vaccine rollout programme began in late December 2020 / early January 2021. The effectiveness of a 
vaccine rollout strategy is dependent on a number of factors, including the administration of the vaccination. 
On 15 February 2021, the Minister for Health announced the location of COVID-19 vaccination centres 
around the country.85 Whilst vaccines were also administered in healthcare settings and by GPs, these so-
called mass vaccination centres were established with the aim of supporting ‘the vaccination of the general 
population in a safe and efficient manner.’86  
 
Similar to the approach taken in the UK, in Ireland, a COVID-19 vaccination may be only administered by 
certain healthcare professionals. An amendment to the Medicinal Products (Prescription and Control of 
Supply) Regulations 2003 in December 2020 provides that registered nurses, pharmacists, paramedics, 
emergency medical technicians, and/or CORU registered Physiotherapist may administer the vaccine.87 
Following this, in February 2021, subsequent amendments were made to add registered optometrists and 
dentists to the list of healthcare professionals who may administer the COVID-19 vaccine.88 
 
A further point worthy of consideration is the tension between policy and practice. Whilst the immunisation 
prioritisation programme has considered and listed priority groups for vaccination, in practice, where excess 
vaccines exist, decisions on distribution ‘on the ground’ must be made. Controversies such as the Coombe 
Hospital, which involved the administration of 16 vaccine doses to family members of hospital employees, 
raised public consciousness on issues of fairness and equitable distribution.89 A similar incident occurred 
subsequently where it was uncovered that the Beacon Hospital gave 20 ‘leftover’ doses of the vaccine to 
teachers in a private school.90 These incidents highlight the importance of guidance for the distribution of 
supplemental vaccines, rather than reliance on individual discretion. This is important not only from the 
perspective of distributive justice, but also, public buy-in and support for the vaccination programme.91 
 
The vaccination roll-out is still ongoing in the RoI.92 Further details of rates of first and second doses of COVID-
19 vaccines across the UK’s four nations, as well as the RoI are set out in Appendix E. More recent statistics 
on the progress of the vaccination rollout in the RoI are currently unavailable following the cyber-attack on 
the Health Service Executive (HSE). 
 
vii. COVID-19 vaccination and consent issues 
 
An issue which required significant consideration in relation to the vaccination rollout in the RoI was that of 
consent, particularly in the context of adults with capacity difficulties. The Assisted Decision-Making 
(Capacity) Act 2015 (ADMCA) was signed by President Michael D. Higgins on 30 December 2015. The ADMCA 
will make substantial changes to the law in this area in the RoI,93 however, the substantive elements of the 
legislation will not be commenced until 2022. As a result, the only legislative framework in place is the Lunacy 
                                                 
85 gov.ie - Minister for Health confirms locations for Ireland’s vaccination centres (www.gov.ie) 
86 Ibid. 
87 Medicinal Products (Prescription and Control of Supply) (Amendment) (No 7) Regulations 2020 inserts Regulation 4F 
into the 2003 Regulations. 
88 S.I. No. 81 of 2021 Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2021. 
89 S Carswell, ‘Coombe hospital chief “deeply regrets” that staff relatives were given Covid vaccines’ The Irish Times. 18 
January 2021. 
90 E Moloney, ‘Beacon Vaccination of Teachers “A Slap in the Face to So Many” – Minister Simon Coveney’ Irish 
Independent, 28 March 2021. 
91 Following these high-profile incidents, guidance was developed and published. See, sequencing-of-covid-19-
vaccination-of-frontline-healthcare-workers.pdf (hse.ie) 
92 For further information, see, https://covid-19.geohive.ie/pages/vaccinations  
93 For further discussion, see, M Donnelly, ‘The Assisted Decision-Making (Capacity) Act 2015: Implications for 
Healthcare Decision-Making’ (2016) 22(2) Medico-Legal Journal of Ireland 65. 
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Regulation (Ireland) Act 1871, which provides for admission to wardship.94 Thus, the issue of consent in the 
context of the vaccine rollout was an important practical consideration.  
 
The importance of this issue was highlighted by the President of the High Court, Ms. Justice Mary Irvine, who 
wrote to the Chief Medical Officer (CMO) on 11 December 2020 in relation to the administration of the 
COVID-19 vaccination to wards of court, and confirmed that there is no requirement to seek a Court Order 
for the administration of the vaccine.95 
 
On 24 December 2020, the Minister for Health signed S.I. No. 698 of 2020: Medicinal Products (Prescription 
and Control of Supply) (Amendment) (No. 7) Regulations 2020. This introduces Regulation 10B which requires 
a vaccine administrator to forward the HSE information on the administration of the vaccine and the patient’s 
personal details including confirmation that prior to the administration of the vaccine, consent was obtained 
or in the event where an individual lacked capacity to consent, ‘the will and preferences of the person was 
established and the administration was for the benefit of the person’.96 
 
Additionally, the HSE Consent to Vaccination for COVID-19 Working Group was established in December 
2020.97 The HSE provided ‘Guidance regarding Consent for COVID-19 Vaccination to public health staff and 
community health organisations on 12 February 2021, which outlines that where an individual has capacity 
to consent, ‘they should make their own informed decision to consent or refuse consent to vaccination’.98 
Furthermore, where an individual lacks capacity, the guidance provides that a healthcare worker can ‘decide 
on behalf of the person that they should receive vaccination and this should be based on the benefit to the 
person and knowledge of their will and preference.’99  
 
Additional guidance was published by the National Consent for COVID-19 Vaccination Working Group on 5 
March 2021, which detailed the principles and processes of consent for vaccination for COVID-19.100 Further 
guidance has been provided by the National Consent for COVID-19 Working Group in relation to adults with 
disabilities who attend a day service,101 and guidance for the vaccination of young people.102  
 
viii. COVID-19 vaccine hesitancy 
 
One of the key challenges in a vaccination rollout of this scale is the issue of uptake. In the RI, the first 
Amárach Public Opinion survey, which specifically addresses vaccines, was published in January 2021. Of the 
1,800 adults surveyed, 70% of participants said they would ‘definitely’ take a COVID-19 vaccine, with some 
37% noting that they had concerns about receiving the vaccine.103 Similarly, a more recent survey published 
on 10 May 2021, found of the 2,200 adults surveyed, 70% would ‘definitely’ take a COVID-19 vaccine when 
it is offered.104 However, some hesitancy has been reported amongst pregnant people. One multi-national, 
cross-sectional survey reported that of 16,000 respondents (pregnant and breastfeeding individuals), 61% 
                                                 
94 There are currently approximately 3,000 wards of court in the RoI. 
95 M Carolan, ‘High Court President Writes to Holohan over Covid-19 Vaccine for Wards of Court’ The Irish Times, 11 
December 2020. 
96 Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 7) Regulations 2020, Regulation 10B. 
97 The Group is chaired by Dr Siobhán Ní Bhriain, National Lead for Integrated Care.  Membership includes an Operational 
Representative; Disability Representative; Mental Health Representative; GP representative; representatives from the 
National Office for Human Rights and Equality Policy; Chairs of the National Consent Advisory Group (Professor Shaun 
O’Keeffe and Professor Mary Donnelly). 
98 guide4staffconsent.pdf (hse.ie) 
99 guide4staffconsent.pdf (hse.ie) 
100 This document also provides detail on digital registration and consent. See, Consent-Principles-5-March-2021 (hse.ie) 
101 process-for-provider-organisations-and-families-to-support-day-service-attendees-to-make-an-informed-decision-
regarding-the-covid-19-vaccine.pdf (hse.ie) 
102 guidance-on-consent-for-vaccination-16-17-years.pdf (hse.ie) 
103 https://www.gov.ie/en/collection/6b4401-view-the-amarach-public-opinion-survey/  
104 https://assets.gov.ie/134643/939c1bce-31ca-4cf4-b9f8-0761da7a40d8.pdf  
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would be willing to be vaccinated.105 The traditional exclusion of this population from clinical trials has proven 
particularly problematic in the context of the pandemic from both the perspective of vaccine uptake amongst 
this cohort and from the perspective of improving maternal and fetal health.106 
 
A related consideration and challenge in the context of the vaccine rollout is that of the refusal of healthcare 
workers to be vaccinated. Vaccination of healthcare workers against COVID-19 is viewed as essential in 
ensuring the health and safety of the workforce, preventing transmission, and protecting healthcare capacity. 
As such, the refusal of healthcare workers to take the vaccine has raised interesting legal questions for 
employers such as the Health Service Executive (HSE). 
 
Recognising the significant challenges posed by healthcare workers who refuse a COVID-19 vaccine, HIQA 
presented recommendations to NPHET for consideration on 8 April 2021.107 HIQA recommended a policy 
based on an ‘intervention ladder’ and also suggested that consideration should be given to a number of 
solutions including redeployment.108 These proposals for redeployment are currently under consideration by 
the HSE, following NPHET’s endorsement of the approach advised by HIQA. 
 
Despite the reported high rates of support for vaccination amongst the public, voices of dissent remain, as 
highlighted by the refusal by some healthcare workers to receive the vaccine and the high-profile case of 
Medical Council v Waters,109 which involved the suspension of a GP for his refusal to administer the COVID-
19 vaccine to his patients. 
 
ix. COVID-19 vaccine passports and immunisation certificates 
 
As part of the containment approach, travel restrictions have been implemented in the UK, and the RoI and 
other European countries, throughout the course of the pandemic. In the RoI, overseas travel was only 
permitted if considered essential, and associated penalties for non-essential overseas travel currently remain 
in place.110  
 
With the vaccination rollout ongoing, focus has re-intensified on the possibility of overseas travel, including 
leisure trips. At a European level, the European Commission announced agreement on the issue of ‘COVID 
passports’ on 20th May 2021.111 From 19th July 2021, the RoI plans to operate the EU Digital COVID Certificate 
(EUDCC) (previously called the Digital Green Certificate) for travel originating within the EU and EEA.112 The 
EUDCC aims to open travel across the EU, with the EUDCC providing proof that an individual travelling has 
either been vaccinated against COVID-19; has received a negative test result; or has recovered from COVID-
19. As such, under the system, fully vaccinated and recovered people holding certificates will be exempt from 
quarantines and other travel restrictions. The certificate will contain key information including name; date 
of birth; date of issue; relevant information about the vaccine / test / recovery; and a unique identifier 
number. Individual Member States will decide how the EUDCC will be implemented as part of national public 
health measures. Further details on the implementation of the EUDCC in the RoI are awaited. 
 
                                                 
105 M Ceulemans et al., ‘Vaccine Willingness and Impact of the COVID-19 Pandemic on Women’s Perinatal Experiences 
and Practices – A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic’ (2021) 18 Int. J. Environ. 
Res. Public Health 3367. 
106 See for example, D. D. Smith et al., ‘Exclusion of pregnant women from clinical trials during the Coronavirus disease 
2019 pandemic: A review of international registries’ (2020) 37(8) Am J Perinatol 792; P Cullen, ‘Half of pregnant 
women attending maternity hospital decline Covid-19 vaccine’ (19 May 2021, The Irish Times). 
107 Advice to NPHET_HCPs who do not avail of vaccination (hiqa.ie) 
108 Ibid. 
109 [2021] IEHC 252. 
110 Health Act 1947 (Sections 31A – Temporary Restrictions) (COVID-19) Regulations 2021. 
111 https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2593  
112 https://www.gov.ie/en/press-release/7894b-post-cabinet-statement-resilience-and-recovery-the-path-
ahead/#international-travel  
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In relation to travel outside the EU, the RoI will broadly follow the EU approach to non-essential travel i.e., 
an ‘emergency brake’ system will be applied to countries where a variant of concern arises.113 Thus, where a 
passenger has valid proof of vaccination and is travelling from a country which is not subject to an ‘emergency 
brake’, no travel-related testing or quarantine will be necessary. In contrast, where a passenger has proof of 
vaccination but is travelling from a country to which an ‘emergency brake’ has been applied, they will need 
to produce a negative PCR test taken no more than 72 hours before arrival, undergo self-quarantine, and 
undergo post-arrival testing. Where the passenger does not have proof of vaccination, they will be subject 
to the same requirements, with the addition of a required period of mandatory hotel quarantine. If an 
emergency brake is applied to a country, the Government advice will be to avoid travel to that country. 
 
x. COVID-19 vaccine injury and redress  
 
Whilst a detailed discussion on vaccine compensation programmes is outside the scope of this WP, it is 
important to note that in contrast to the UK,114 at present in the RoI, there is no State vaccine compensation 
scheme. This was an issue which was identified by an Expert Group appointed to review the law of torts and 
the current systems for the management of clinical negligence claims in 2018. In its report, the Expert Group 
observed that ‘there is a strong moral argument that the State, which actively encourages vaccination, should 
accept responsibility for those who suffer harm as a result.’115 The Group ultimately recommended that a 
vaccine compensation scheme be established ‘as a matter of urgency.’116 
 
More recently, a vaccine injury compensation programme overview was prepared and presented to the 




PART IV: COVID-19 AND THE ISLAND OF IRELAND  
 
We also want to briefly highlight some key issues relevant to understanding the dimensions of managing the 
COVID-19 pandemic on the island of Ireland, which could be understood as single epidemiological unit in 
terms of the spread of the virus. Viewing the island in this way, however, presents a range of unique 
challenges in public health terms, given the island’s political history and in particular the ‘border question’.  
 
From the UK’s point of view, NI is considered a devolved jurisdiction, comprising six counties in the North-
East of the island of Ireland. While this jurisdiction was formally created in 1921, its constitutional status, 
including whether it should remain part of the UK or form part of a united Ireland, remains contested. During 
the period of what is commonly known as ‘The Troubles’, devolved government in NI was suspended on 
several occasions, with direct rule being imposed by the UK government during these periods.  
 
In 1998, the Good Friday Agreement (or Belfast Agreement) was adopted, which provided for the re-
establishment of devolved power-sharing institutions. The Agreement was based on the principle of consent 
in the context of the constitutional position of Northern Ireland and a right to self-determination subject to 
the consent of the majority in NI and RoI.119 Under the Good Friday Agreement, anyone born in NI can identify 
as an Irish citizen (and, therefore, hold an Irish/EU passport), as a British citizen (and, therefore, hold a UK 
                                                 
113 Ibid. 
114 Vaccine Damage Act 1979. 
115 Mr Justice Charles Meenan, Expert Group Report to Review the Law of Torts and the Current Systems for the 
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passport) or both. One of the unforeseen outcomes of this is potential problems associated with the EU 
Digital Covid Certificate.  
 
A lack of clarity currently exists in relation to what the position will be of Irish (thus EU) citizens who live in 
NI and who were given vaccines under the NHS system. How will they be included on the EU Digital Covid 
Certificate? National authorities are currently responsible for issuing the certificate. It will exist as a paper 
certificate as a QR code on a mobile phone app. It is unclear, at this moment, how Irish citizens will be able 
to obtain the EU Digital Certificate. It is also unclear if the Irish government will be issuing certificates to Irish 
citizens who live in NI (which obviously includes a significant population of NI) or only those who reside in 
RoI.  
 
Political tensions persist over the border between NI and RoI. In recent times, this has been exacerbated by 
the UK’s decision to leave the EU, given that the North-South border on the island of Ireland has now become 
the sole land border between the UK and the EU. In the wake of Brexit, the NI Protocol has been a source of 
ongoing controversy. 
 
It is also important to keep in mind, NI power-sharing institutions were only again restored in January 2020 
following a period of direct rule in the period 2016-2019. It meant that the NI Executive was barely bedded 
in before it was forced to address the implications presented by the COVID-19 pandemic on a local basis, 
shared island basis and in terms of its relations with the other nations in the UK, more generally.  
 
Health is a devolved matter and therefore it is primarily a matter for the NI Executive and the NI Assembly to 
make policy and law in this area.120 Once the Coronavirus Act 2020 was in place, the NI Executive moved 
quickly to adopt its own laws to enable it to impose lockdown measures on a local basis.121 It has continued 
to adapt such measures through successive waves of the pandemic.  
 
As between the NI and RoI jurisdictions on the island of Ireland, a number of nuanced similarities and 
differences between the approaches adopted in the jurisdictions have emerged. Underpinning these actions 
and, in some cases, inactions, lie values and ethics. These similarities and differences have emerged in light 
of the coming together of occasionally contrasting medical advice and political reasoning in the jurisdictions.  
 
For the most part, these two factors have been positive influences on vaccine practices, but, occasionally, 
perhaps as a consequence of sometimes fraught political allegiances and sub-terranean tribalism, the 
alignment of medical advice, political action and subsequent decisions-making in respect of vaccines has not 
always been cohesive, coherent or fully reflective of joined-up thinking.  
 
Notwithstanding the fact that NI and the Irish Republic are considered a single epidemiological unit and the 
fact that COVID-19 recognises no geographical borders, there was and is no particular consensus in respect 
of agreed vaccination actions across the island. Values that are held about nationality and whether that 
nationality is orange or green have, perhaps, led to decisions being made in line with practices in GB or RoI, 
according to political affiliation rather than medical necessity.  
 
Similarities and differences between the NI (UK) and RoI: 
 
 Unlike the RoI (via the European Medicines Agency), the UK regulator (MHRA) has not authorised the 
Johnson & Johnson/Janssen vaccine, which only requires the administration of one dose. 
 Different time limits adopted in NI and RoI in respect of administration of first and second doses of 
the AZ and Pfizer vaccines.  
 COVID-19 vaccination rates and vaccine hesitancy are different in NI and RoI. 
 The issue of consent in relation to COVID-19 vaccination differs as between NI and RoI. 
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 Vaccine injury redress differs as between the UK and RoI. 
 Different approaches adopted in terms of prioritising age groups for vaccination, particularly with 




PART V: VALUES AND VARIATION: COVID-19 VACCINATION IN THE UK AND IRELAND 
 
This WP addresses the issue of values as they pertain to practices surrounding immunisation and COVID-19. 
The ethical underpinning for the vaccination processes provided guidelines for societal conduct aimed at 
maximising the efficacy of immunisation approaches. Values are considered in this WP as, essentially, putting 
ethics into action.  
 
Ethically appropriate mechanisms should be linked to the values, principles and ideals that are held by 
society. The interplay between ethics and values is not a semantic one. In the context of this WP, the value 
that is given to the age, employment, nationality, vulnerability and capacity or otherwise of the person is 
linked to the vaccination choices and opportunities that are provided.  
 
Thus, the values that are held in respect of all these variables have resulted in people being treated differently 
because of their age, personal characteristics and medical history. This WP highlights the fact that a system 
of values lay behind and lies behind many of the decisions that have been made and are being made in 




There is a very broad values-derived question about fairness and vaccination opportunities that needs to be 
addressed. In-depth consideration of this ethical issue is beyond the scope of this WP, but this issue is likely 
to be considered in much of the future international discourse surrounding sharing of resources in global 
medical emergencies and related inequity in practice. The issue of fairness is also, however, a local one. It 
still applies to the decisions made in respect of prioritisation of vaccines. Values are something that 
determine priorities that are adopted, and the current age-specific/vulnerability focused vaccination 
procedures adopted appear to give priority to older and more vulnerable people. Valuing people whose lives 
may have been devalued in the earliest stages of COVID-19, as evidenced by the high death rates in care 
homes, may be an appropriate course of action. However, the scientific community who are making the 
decisions about who is to be vaccinated are likely to be older. It may be significant (at least subliminally) that 
they have chosen to prioritise the vaccination of the cohort that best matches the values of the scientific 
community itself. 
 
Within the general population in both NI and RoI, there is a commonly held view among many that some 
vaccines are ‘better’ than others. Someone who has a fear of getting a blood clot, for example, may wish to 
be given the Pfizer vaccine instead of the AZ vaccine. This creates a conundrum in relation to whether or not 
people should be allowed to choose which COVID-19 vaccine they receive. This gives rise to the ethical 




There has been much discussionabout the way in which vaccine-eligibility have been prioritised. They have 
been focused on vulnerability (age and health status) as well as health/social care workers. There have been 
calls from differing professions, such as teachers, to receive prioritisation. This brings to bear the issue of 
‘value’ and why one cohort of people should be prioritised over another. One may argue that someone 
working in a supermarket (on the so-called COVID-19 frontline) who is providing an essential service should 
be prioritised over someone who is not working, but fits into a higher position on the priority scale. The same 
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could, equally, be said about the Gardaí/police and many other work contexts. But if that is the case, where 




To date, there has been a common drive towards vaccine and scientific evidence conclusively supports the 
vaccination of people. Academic and scientific voices that are vocal in their support of vaccines are heard 
loudly and consistently. These voices are valued in political, medical and mainstream media arenas. Less 
value is attached to those who are anti-vaccines: their voices are muted or derided or ignored or mocked, 
and they are certainty given little value. This workshop will look at the value that is ascribed to people who 
purport to hold anti-vaccine views. This aim of this approach is not to give voice to what may be irrational, 
pseudo-scientific theory, but this issue is highlighted in so far as it is possible that the muting of anti-vaccine 
proponents can give rise to a sub-culture of anti-vaxxers who find that their opinions are valued more in a 
cult-style milieu. This, ultimately, could have a negative impact on vaccination in the population and bears 
inclusion in our discourse.  
 
Obviously, the key to future cohesion in the development of services to arrest the spread of COVID-19 will 
be the presence of increased cooperation and solidarity between the two jurisdictions. In such a scenario, 
actions would be taken out of medical and scientific necessity rather than along the intransigence of deeply 
embedded political lines. At a very human level, the people of NI and RoI are joined by the common purpose 
of the need to strive for health and wellbeing, which has been highlighted by COVID-19. 
 
Public-private dimensions (market/economy) 
 
The pandemic has had an undeniable impact on the global economy. The rollout of a vaccine, therefore, is 
an important aspect of planned economic recovery and has been described as ‘an exit strategy.’122 Whilst a 
detailed discussion on the balance between economic costs and public health considerations is outside the 
scope of this WP, it is prudent to briefly discuss this issue in the broader context of values and variation.  
 
A key consideration for policy makers during the pandemic has been the balance between mitigating against 
the negative impact of lockdown measures on the economy and wider public health concerns. Globally, some 
countries have adopted more aggressive prevention and control strategies, whilst others have adopted 
‘mitigating spread measures’.123 Such actions have prevented morbidity. Whilst the vaccine rollout remains 
ongoing, in the UK and the RoI, businesses and industries previously closed by the pandemic have begun to 
re-open. Re-opening of the economy needs to involve a careful balance of public health and economic 
concerns, with many still awaiting a vaccine in the RoI. In the context of the vaccine rollout, particularly in 
the RoI, questions around the prioritisation of vaccination of workers in frontline positions e.g. supermarket 
workers; teachers; Gardai, were raised.124 However, ultimately an age-based approach to the rollout of the 
vaccine was adopted in the RoI and the UK. 
 
More recently, in the UK, variants have brought additional challenges and localised lockdown measures have 
been considered. Similarly, in the RoI, a surge of cases in Limerick raised questions about the possibility of 
imposing localised lockdowns.125 Thus, it appears that the balance between re-opening the economy whilst 
maximising public health continues to remain a key consideration. 
 
                                                 
122 R MacIntyre, ‘Navigating Post-Vaccine COVID-19 Futures in the Health and Economic Context’ (2021) The Lancet 
Infectious Diseases, published online March 18, 2021. https://www.thelancet.com/journals/laninf/article/PIIS1473-
3099(21)00126-2/fulltext 
123 C Seghieri et al., ‘Looking for the Right Balance Between Human and Economic Costs during COVID-19 Outbreak’ 
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Centre-periphery relation, urban-rural divide and border communities 
 
The JCVI provides UK departments with advice in relation to immunisation. There are no representatives 
from NI on the JCVI. Does this GB-centred approach have an adverse impact upon the devolved nature of the 
Department of Health in NI, and does it reduce the autonomy of that Department and, indeed, of the 
Executive itself?  
 
 
Human rights  
 
Human rights are value-based instruments of thought of legal action and a vehicle for change. There are 
questions around human rights of those who have been vaccinated and those who never were vaccinated 
and who sadly died and whose right to life may have been breached by the failure to protect their life before 
the vaccinations were introduced.  
 
Is the adoption of a vaccine passport for NI/RoIa realistic, appropriate and ethical solution or would it result 
in a two-tiered, unfair and unethical system? The Council of Europe’s Committee on Bioethics has indicated 
that such a passport would need to carefully considered and to be human rights’ compliant.126 The 
Committee agrees with the Council of Europe’s Secretary General, who stated that  
 
combating the current pandemic depends, above all, on the increased efforts to produce and 
administer vaccines, with particular attention to people in vulnerable situations, so that restrictions 
to individual freedoms and constraints imposed can be progressively reviewed as the population 
acquires greater immunity, taking into account acquired scientific knowledge.127 
 
Under the European Convention on Human Rights (ECHR), freedoms can be curtailed as long as they are 
prescribed by law, proportionate and necessary. The Committee is particularly concerned about when a 
vaccine passport could be used to allow for ‘exclusive access to services or to specific areas or as a 
requirement for entering a country.’128 The issue of personal data that could be contained in a digital 
vaccination certificate could become an ethical minefield. According to the Committee, ‘the processing of 
such data and information requires a particular high level of protection.’129 The Committee also refers to the 
issues of ‘scientific uncertainty’ and the ‘impact on social cohesion and solidarity.’130 For example, the vaccine 
passport could cause, on one hand, a reason for people to be vaccinated or, on the other hand, reduce public 




Sometimes values are not definitive, intransigent codes of reference for behaviour or belief. At other times 
they define the very psyche and personhood of the individual. Beyond the parameters of these two extremes 
lie gradients of importance that can be ascribed to values. Suffice to say that values form part of the 
vaccination decision-making process. The Nuffield Council on Bioethics states that social norms can be a 
significant player in decision-making. In a society where vaccination is regarded as ‘normal’ then it is more 
likely that a person will decide to be vaccinated.132 Religious or philosophical beliefs/values can have an 
                                                 
126 Council of Europe Newsroom, ‘Vaccine Passports: Protecting Human Rights and Personal Data’, 4 May 2021/  
https://www.coe.int/en/web/portal/-/vaccine-passes-protecting-human-rights-personal-data  
127 Committee on Bioethics, ‘Statement on Human Rights Considerations Relevant to “Vaccine Pass” and Similar 
Documents’, 4 May 2021. https://rm.coe.int/dh-bio-2021-7-final-statement-vaccines-e/1680a259dd  
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impact on whether or not someone is vaccinated.133 Equally, ‘[i]deas about naturalness are sometimes 
invoked as a reason to reject vaccination’.134 The challenge, into the future, is to ensure that a vibrant 
discourse around vaccination occurs that is founded upon the rigour of scientific fact. For this discourse to 
be beneficial, however, the values that people have as they pertain to this aspect of medical care need, at 
the very least, to be acknowledged.  
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APPENDIX A 
 
CHRONOLOGY: COVID-19 VACCINATION IN THE UK 
 
 




 The UK government launches the Vaccine Taskforce to combat COVID-19, leading efforts 
to develop, manufacture, and procure vaccines for the UK and globally. 
 Late April 
2020 
 The UK announces £42.5 million for clinical trials conducted by Imperial College and at the 
University of Oxford.  
 The UK begins the first human trials for COVID-19. 
 Human trials for the Oxford-AstraZeneca vaccine begin. 
 
May 2020  The UK promises another £84 million to help fund the mass production of the vaccine 
being trialled by the University of Oxford.  
 The UK has made provisional agreements for up to 100 million doses of the Oxford – 
AstraZeneca vaccine.  
 
June 2020  An announcement is released that the University of Oxford would be partnering with 
AstraZeneca to begin manufacturing the vaccine, despite not yet having received clinical 
approval. This deal is reached with a view to stockpile the vaccine in advance of its 
approval to facilitate and expedite deployment. 
 Imperial College begin human trials. 
 
July 2020  The UK signs a deal for 90 million doses of vaccines from Pfizer-BioNtech and Valneva. 
 The UK has made provisional deals for up to 60 million doses of the Sanofi-
GlaxoSmithKline vaccine. 
 A major breakthrough is achieved in the sprint to find an effective vaccine, with trials 
suggesting the Oxford-AstraZeneca vaccine provides immunity.  
 
August 2020  The UK has made provisional deals for up to 60 million doses of the Novavax vaccine. 





 The UK has made provisional deals for up to 190 million doses of the Johnson & Johnson 
vaccine. 




 Changes to the Human Medicine Regulations to support the rollout of COVID-19 vaccines. 
 The JCVI issues advice on which groups should be prioritised for vaccination once a 
suitable vaccine candidate is approved.  
 UK announces plan to go ahead with ‘human challenge’ trials for a COVID vaccine, 
involving approx. 90 persons 
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 UK signed deal for 5m doses of Moderna vaccine, which announced 95% effectiveness. 
 The UK has made provisional deals for up to 405 million doses of the Curevac vaccine. 
 Pfizer and BioNTech announce that, after conducting the final efficacy analysis in their 
Phase 3 study, their vaccine candidate met all of the study’s primary efficacy endpoints. Its 





 Matt Hancock announces plans to set up vaccine centres all throughout the UK. 
 Boris Johnson states there will be no forced vaccination in UK. 
 Health officials have warned that plans for mass testing in England threaten to be a 
distraction to other priorities, such as the rollout of a vaccine. 
 New role of Parliamentary Under-Secretary of State for COVID-19 Vaccine Deployment set 





 UK approves Pfizer/BioNTech vaccine (Comirnaty). 
 First batch (800,000) of Pfizer/BioNTech vaccines arrive in the UK on 3rd. 
 COVID-19 vaccines added to VDPS, pursuant to the Vaccine Damage Payments (Specified 
Disease) Order 2020, SI 2020/1411 
 First patient receives the Pfizer/BioNTech vaccine on 8th. 






 Vaccinations using the Pfizer/BioNTech vaccine begin in Scottish care homes 
 More than 70 vaccination sites in operation in England. 
 UK approves Oxford/AstraZeneca vaccine for use (AZD1222). 
 JCVI Guidance on Priority Groups for COVID-19 Vaccination published. 







 The first patient in England received the Oxford-AstraZeneca vaccine. 
 Rollout of the Oxford/AstraZeneca vaccine begins in Northern Ireland on 04th. 
 UK approves Moderna vaccine for use (MRNA-1273). 
 NHS England announces that NHS health and social care staff will be given immediate 
priority on receiving the vaccine, with the majority vaccinated before February. 
 The first vaccination strategy for Wales is published on 13th. 




 AstraZeneca announces that it will prioritise its delivery of vaccines to the UK, over 
delivering vaccines to the EU, as it signed its contract with the UK first. 
 Amid ongoing rows over vaccine shortfalls in the EU, the European Commission announced 
the introduction of control on vaccines made in the bloc, including Northern Ireland 
February 
2021 
 UK signed a deal for an extra 40 million doses of VLA2001 (Valneva) 
 NHS England confirms that every older care home resident in England has been offered a 
COVID vaccine. 
 England reaffirms they will not be introducing a vaccine passport. 
 New study suggests Oxford/AstraZeneca offers minimal protection against the South 
African variant. 
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 England - All top four priority groups given their first dose on 14th, meeting the target of 
vaccinating 15 million before the 15th. 
 UK government announces that it aims to offer all adults over 18 a vaccine before 31 July 
2021. 




 MHRA issues guidelines allowing fast-tracked approval of new versions of existing covid 
vaccines developed to fight variants. 
 Health Minister Robin Swann rules out the idea of vaccine passports in Northern Ireland. 
 Further dispute with EU over comment that the UK placed ‘outright ban’ on exports of 
vaccines produced in the UK. 
 MHRA issues a statement: no evidence linking Oxford/AstraZeneca vaccine to increased 
risk of blood clots. 
 WHO: no evidence linking the Oxford/AstraZeneca vaccine to blood clots 
 Health officials in Northern Ireland announce that the use of the Oxford/AstraZeneca 
vaccine will continue, despite being suspended in the Irish Republic amid concerns about 
links to blood clots in Norway. 
 Chief Medical Office for Scotland Gregor Smith affirms confidence in the 




 England begins to vaccinate those aged 50 and over 
 A letter from NHS England warns of a ‘significant reduction’ in the weekly supply of COVID 
vaccines – fewer AstraZeneca vaccinations will be available than expected. 
 European Commission threaten to withhold vaccine exports to the UK (and any other non-
EU countries) not supplying doses in a reciprocal manner. Scotland will get 500,000 fewer 
vaccine doses and Wales will receive 250,000 fewer vaccines over the next month due to a 
reduced supply of UK vaccines 
 Health Minister Robin Swann says that all adults in Northern Ireland will receive their first 
vaccine by the end of July, in spite of an expected reduction in UK vaccines. 
 Pam Kelly, Chief Constable of Gwent Police, calls for frontline police officers to be 
prioritised for the COVID vaccine. The Welsh Government in response says there is 
insufficient evidence to support vaccination by occupation 
 A spokesperson for Prime Minister Boris Johnson declares that there are no surplus 
vaccines for the UK to share with other countries. 
 JCVI: households where someone has a weakened immune systems should receive priority 
for vaccination. 
 First Minister of Northern Ireland suggests once all adults in the UK are offered two doses 




 Wales is on target to become the first UK nation to offer all nine priority groups a first 
vaccine, and is on track to do so by Easter Sunday (4 April). 
 MHRA finds 30 cases of rare blood clots in people after receiving the Oxford/AstraZeneca 
vaccine, but that benefits continue to outweigh the risks. MHRA confirms seven blood clot 
deaths among the 18 million vaccinated, unclear if these are a side effect. 
 Wales meets target on 5th to offer vaccine to all nine priority groups. 
 First dose of the Modern vaccine administered 
 UK advises against giving the Oxford/Astrazeneca vaccine to under 30s. Adults under 30 
are to be offered an alternative, following JCVI guidance of Oxford-AstraZeneca and blood 
clots. 
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 Dr Richard Roberts, head of Wales's vaccination rollout, confirms one person in Wales has 
developed a blood clot following administration of the Oxford–AstraZeneca vaccine. 
 UK confirms everyone in the top nine priority groups has been offered their first COVID 




 JCVI: changed advice for pregnant women. Recommended to receive the vaccine at the 
same time as others in their age group, and that Pfizer/Moderna are preferable. 
 Figures published by Public Health Wales indicate that vaccine uptake among black, Asian 
and other ethnic minority groups is 10% lower than in white communities, though the gap 
has narrowed slightly since February. 
 Public health officials in Scotland confirm that a digital scheme to enable people to prove 
their vaccine status is under development. 
 UK identifies 55 new cases of the Covid-19 variant first identified in India. 
 EU has launched a legal case against AstraZeneca – accused of not having a timely plan for 
the delivery of vaccines.  




 The UK wide decision to offer adults under 40 an alternative to the Oxford AstraZeneca 
vaccine could delay Northern Ireland’s vaccination programme. 
 The UK government confirms that from 17 May, those in England with both vaccines will 
be able to use the NHS app as a vaccine passport.  
 The gap between first and second vaccinations is narrowed to eight weeks for people in 
the top nine priority groups. 
 Concern over increased number of cases of the Indian variant, may be necessary to 
reimpose "economic and social" restrictions at a local or regional level and bring forward 
second doses in heavily impacted areas. 
 Research carried out by Public Health England suggests COVID vaccines have saved 11,700 




 Prime Minister Boris Johnson says there is "increasing confidence" COVID vaccines work 
against all strains of the virus, including the Indian variant.  
 Members of the public are urged to take part in a trial of a third COVID vaccine to 
determine its effectiveness against future strains of the virus. 
 Scotland – people travelling overseas will be able to access a vaccine certificate, either 
online or by request through post. 
 Failures in England's Test and Trace system are thought to be partly responsible for a surge 
in Indian variant COVID after eight local authorities did not have full access to the data for 
three weeks during April 
 Research carried out by Public Health England shows both the Pfizer and AstraZeneca 
vaccines are effective against the Indian COVID variant. 
 Janssen Vaccine approved for use in the UK 
 The World Health Organization changes its COVID variant naming policy, adopting Greek 




 The UK records its first day with zero COVID-related deaths since March 2020; 3,165 new 
cases of the virus are announced. 
 EU Gateway (interconnection of national systems) goes live, as part of the EU’s digital 
COVID-19 certificate programme. 
 Pfizer-BioNTech vaccine approved for 12 to 15-year olds by the MHRA, concluding that the 
benefits outweigh the risks.  
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Joint Committee on Vaccination and Immunisation138 
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Medicines and Healthcare products Regulatory Agency139 
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Public Health England 
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EXPLANATORY NOTES: 
135 These Regulations consolidate the law of the UK concerning medicinal products for human use, and were amended 
in October 2020 to facilitate authorisation and deployment of vaccinations. 
136 The BMA is the trade union and professional body for healthcare professionals in the UK. 
137 The EMA is an agency of the European Union responsible for the evaluation, approval and supervision of medical 
products. Until the end of December 2020, and as part of the transition period, vaccines could be licensed by the EMA 
and this authorisation would automatically be valid in the UK, however following this, such responsibilities have fallen 
to the remit of the MHRA. 
138 The JCVI Is an independent advisory committee that advises the Government health departments in the four UK 
nations on immunisation, making recommendations concerning vaccine schedules and safety. 
139 The MHRA is an executive department of the Department of Health and Social Care that regulates medicines, 
medical devices and therapies in the UK. Any vaccine submitted for approval after the end of the transition period in 
January 2021 will be assessed directly by the MHRA. 
140 This provides for vaccine damage payments, a one-off tax-free payment of £120,000 for persons severely disabled 
as a result of vaccination against certain diseases. 
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APPENDIX B  
 
CHRONOLOGY: COVID-19 VACCINATION IN THE REPUBLIC OF IRELAND 
 
 
DATE                                  EVENT 
2020 
 Late April 
2020 
 Human trials for the Oxford/AstraZeneca vaccine begin. 
May 2020  The WHO announces that there are 108 potential vaccines in development around the 
world, with 8 approved for clinical trials. 
 Human trials for the Pfizer/BioNTech vaccine begin. 
June 2020  The Inclusive Vaccine Alliance (comprising of France, Germany, Italy, and the Netherlands) 
reaches agreement with Oxford/AstraZeneca to supply up to 400 million doses of its 
COVID-19 vaccine with a view to make it available to other European countries. 
 The European Commission Releases the EU Strategy for COVID-19 Vaccines announcing 
that it will ‘implement a joint approach going forward’ with the Inclusive Vaccine Alliance.  
July 2020  The European Commission concludes exploratory talks with pharmaceutical company 
Sanofi-GSK to potentially purchase 300 million doses of their COVID-19 vaccine. 
August 2020  The European Commission concludes exploratory talks with three pharmaceutical 
companies for the potential purchase of vaccines; Johnson & Johnson (up to 400 million 
doses), CureVac (initial purchase of 225 million doses), and Moderna (up to 160 million 
doses). 
 The European Commission signs its first vaccine contract with Oxford/AstraZeneca to 
purchase an initial 300 million doses and an option of 100 million more. 
 The EU pledges a €400 million contribution to support the COVID-19 Vaccine Global Access 
Facility (COVAX).  
September 
2020 
 The European Commission concludes exploratory talks with Pfizer/BioNTech to potentially 
purchase up to 300 million doses of their vaccine candidate. 
 Oxford/AstraZeneca vaccine trial pauses globally as part of the standard review process 
after a participant experiences an unexplained illness. 
 The European Commission signs its second vaccine contract with Sanofi-GSK for the 
purchase of up to 300 million doses. 
October 2020  The European Medicine’s Agency (EMA) starts its first rolling review of a COVID-19 vaccine 
candidate (Oxford/AstraZeneca) and later starts a rolling review of the Pfizer/BioNTech 
vaccine. If successful, the vaccines will be evaluated for marketing authorisation. 
 The European Commission signs its third vaccine contract with Johnson & Johnson for an 
initial purchase of 200 million doses and the possibility to purchase an additional 200 




 The National Immunisation Advisory Committee (NIAC) presents interim 
recommendations identifying priority groups for a future COVID-19 vaccine. 
 Pfizer/BioNTech announce that, after conducting the final efficacy analysis in their Phase 3 
study, their vaccine candidate met all of the study’s primary efficacy endpoints. Its analysis 
found that the vaccine is 95% effective. 
 The European Commission signs its fourth vaccine contract with Pfizer/BioNTech for an 
initial purchase of 200 million doses with an option to request an additional 100 million 
doses. 
Electronic copy available at: https://ssrn.com/abstract=3887603
University of Edinburgh School of Law Working Paper No 2020/16 
 




 The European Commission signs its fifth vaccine contract with CureVac for an initial 
purchase of 225 million doses and an option to request an additional 180 million doses. 
 The EMA starts a rolling review of the Moderna vaccine candidate. Final results show the 
Moderna vaccine to be 94% effective. The European Commission signs its sixth vaccine 
contract with Moderna, for the purchase of an initial 80 million doses with an option to 
request a further 80 million doses. 
 The Immunisation Strategy Group is established, chaired by the Department of Health.  
 The High-Level Task Force, established by the Government, meets for the first time. The 
chair is Professor Brian MacCraith. The Task Force will work with the DOH and the HSE to 





 The Government approves an advance purchase agreement for 875,000 doses of the 
Moderna vaccine. 
 The EMA starts a rolling review of Janssen’s vaccine candidate.  
 The Minister for Health announces the Allocation Strategy for COVID-19 vaccines. One 
week later the Minister announces the National COVID-19 Vaccination Strategy and an 
Implementation Plan prepared by the High-Level Task Force. 
 The president of the High Court, Ms. Justice Irvine, writes to the CMO concerning the 




 The European Commission concludes exploratory talks with Novavax to potentially 
purchase up to 200 million doses of their vaccine candidate. 
 The EMA recommends the Pfizer/BioNTech vaccine as the first COVID-19 vaccine for 
authorisation in the EU. The European Commission authorises the vaccine for use 
following this. 
 NIAC provides recommendations to the DOH for the COVID-19 vaccination rollout. 
 The Minister for Health signs S.I. No. 698 of 2020: Medicinal Products (Prescription and 
Control of Supply) (Amendment) (No. 7) Regulations 2020 authorising COVID-19 vaccines 
to be administered in the State.  
 The first batch of Pfizer/BioNTech vaccines arrive in the Republic (9,950 doses). 




 The EMA recommends the Moderna vaccine for authorisation in the EU, which is then 
authorised for use by the European Commission. 
 The Minister for Health announces that 875,000 doses of the Moderna vaccine have been 
ordered by the Government and 3.3 million doses of the Pfizer/BioNTech vaccine have 
been ordered. 
 The COVID-19 vaccine rollout begins in privately-owned and voluntary nursing homes. The 
Minister for Health also announces and acceleration of the vaccination programme, using 
its one-week buffer to speed up vaccinations. 
 The European Commission proposes to purchase up to 300 million additional doses of the 
Pfizer/BioNTech vaccine, with 75 million doses available by the second quarter of 2021. 
 The European Commission concludes exploratory talks with Valneva with a view to 
purchasing up to 60 million doses of their vaccine candidate. 
 The first shipment of Moderna vaccines arrive in Ireland (3,600 doses). 
Late January 
2021 
 Approximately 1,800 medical staff are vaccinated in centres nationwide; almost all GPs in 
the State have received their first dose of the Moderna vaccine. 
 The Government requests early deliveries of the Oxford/AstraZeneca vaccine, subject to 
EU approval. 
 It is revealed that the Coombe Women & Infants University Hospital in Dublin gave 16 
excess vaccine doses to family members of hospital employees. The HSE is asked to 
compile a report into the administration of ‘spare’ vaccines to non-frontline staff following 
the hospital controversies.  
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 The European Commission adopts a Communication calling on Member States to speed up 
the roll out of vaccines across the EU. 
 The EMA recommends COVID-19 vaccine Oxford/AstraZeneca for authorisation in the EU. 
 Ireland is expected to receive 300,000 fewer doses of the Oxford/AstraZeneca vaccine as a 




 The EMA starts a rolling review of Novavax’s COVID-19 vaccine candidate. 
 The HSE’s Consent for COVID-19 Vaccination Working Group publishes a Guidance Note 
on ‘Supporting the consent process in those who lack capacity and are anxious/or refusing 
vaccination’ 
 The first shipment of Oxford/AstraZeneca vaccines (21,600 doses) arrives in Ireland. 
 New study suggests Oxford/AstraZeneca vaccine offers minimal protection against the 
South African COVID-19 variant. 
 The High Court rules that the HSE was correct not to seek court orders to have the COVID-
19 vaccine administered to a ward of court against her wishes. 
 The HSE circulates a ‘Guidance regarding Consent for COVID 19 Vaccination’. 
 The EMA starts a rolling review of CureVac’s COVID-19 vaccine candidate. 
Late February 
2021 
 The Minister for Health announces the locations of 37 COVID-19 vaccination centres 
around the country. 
 Community vaccination of Cohort 3 (over 70s) begins, with those 85 years and older the 
first to be vaccinated at selected GP practices. 
 The European Commission approves a second contract with Moderna, for an additional 
purchase of 300 million doses until 2022. 
 NIAC publishes updated recommendations on Priority Groups for vaccinations, adding 
new medical conditions to the list and advising that 16-69 year olds at very high risk 
should be vaccinated next after the over 70s. 
 The Minister for Health signs S.I. No. 81. Of 2021 Medicinal Products (Prescription and 
Control of Supply) (Amendment) (No. 4) Regulations 2021 which adds registered 
optometrists and registered dentists to the list of vaccine administrators. 
 The Government publishes a revised plan for living with and reducing the spread of 
COVID-19, ‘Resilience and Recovery 2021 Plan: The Path Ahead’. 
Early  
March 2021 
 The National Consent for COVID-19 Vaccination Working Group publish the ‘Consent for 
vaccination for COVID-19: Guiding Principles’. 
 More than half a million vaccines have been administered in the State. 
 Vaccination of Cohort 4 (those aged 16-69 at very high risk) begins. 
 The European Commission orders four million more doses of the Pfizer/BioNTech vaccine 
for quick delivery to tackle hotspots. 
 The EMA begins reviewing the Oxford/AstraZeneca vaccine after Austrian authorities and 
other Member States suspend use of the vaccine following reports of blood clots. 
 The Johnson & Johnson’s vaccine Janssen is the fourth to be authorised in the EU. 
 NIAC recommends the temporary deferral of the Oxford/AstraZeneca vaccine. Some 
30,000 people due to receive it will have their vaccination rescheduled. 
 WHO say there is no evidence linking the Oxford/AstraZeneca vaccine to blood clots. 
Late March 
2021 
 The European Commission proposes to create a Digital Green Certificate to facilitate safe 
free movement inside the EU during the COVID-19 pandemic. 
 The EMA concludes its preliminary review of blood clots in people vaccinated with the 
Oxford/AstraZeneca vaccine and confirms that the benefits continue to outweigh the risk 
of side effects. NIAC recommends resuming the rollout. 
 It is revealed that 20 excess doses from the Beacon Hospital’s vaccine programme, were 
used to vaccinate teachers and staff from a school near Bray. The Minister for Health calls 
for the HSE to suspend vaccine operations at the hospital following the controversy. 
 The European Commission announce that Oxford/AstraZeneca must deliver vaccines to 
the EU before it can export doses elsewhere in the world. 
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 NIAC recommends that the vaccine rollout be changed to an age-based system following 
the current priority groups being vaccinated.  
 There is controversy among teachers’ associations and Gardaí representatives following 
the change to the vaccine rollout.  
Early April 
2021 
 Gardaí and teachers demand that the Government ensure they are vaccinated earlier. 
 The EMA concludes that unusual blood clots with low blood platelets should be listed as 
very rare side effects of the Oxford/AstraZeneca vaccine. 
 One millionth vaccine dose is administered. 
 The HPRA investigates the first ever case of a blood clot associated with the 
Oxford/AstraZeneca vaccine. 
 The EMA starts a review to assess reports of ‘unusual blood clots’ in people who received 
the Johnson & Johnson Janssen vaccine in the US. 
 NIAC announces that the Oxford/AstraZeneca vaccine is not recommended for those aged 
under 60 years, including those at very high or high risk. 
 Johnson & Johnson announce that they will proactively delay the rollout of the Janssen 
vaccine in Europe after reports of blood clots. 
Late April 
2021 
 The HSE’s online portal for vaccination opens for those aged 65-69. This begins the 
vaccination of Cohort 5, people aged 60-69.  
 The EMA concludes that a warning about unusual blood clots with low blood platelets 
should be added to the Janssen vaccine product information. 
 NIAC publishes recommendations for COVID-19 vaccination in pregnancy. 
 The EU launches legal action against Oxford/AstraZeneca ‘for not respecting its contract 
for the supply of Covid-19 vaccines and for not having a “reliable” plan to ensure timely 
deliveries.’ 
 NIAC publishes updated recommendations for COVID-19 vaccination after laboratory 
confirmed infection and new recommendations that mRNA vaccines are preferable for 
those aged 50 and younger. 
Early May 
2021 
 The EMA starts evaluating the use the Pfizer/BioNTech vaccine in young people aged 12 to 
15. 
 Registration on the HSE’s online vaccination portal begins for Cohort 9, people aged 50-59. 
 The HSE considers proposals for the redeployment of HSE staff who refuse Covid-19 
vaccines. 
 The first doses of the Johnson & Johnson Janssen vaccine are administered. 
 The HSE suffers a major ransomware cyberattack that causes all of its IT systems to be shut 
down, but the vaccine registration portal is restored later the same evening. 
Late May 
2021 
 Following NIAC recommendations, people in their 40s are to be given choice of 
Oxford/AstraZeneca or Janssen vaccines. 
 Registration on the HSE’s online vaccination portal begins for people aged 45-49. 
 The European Commission signs a third contract with Pfizer/BioNTech which reserves an 
additional 1.8 billion doses between the end of 2021 to 2023. 
 The European Parliament and Council reach agreement on the Commission’s proposal for 
a Digital COVID Certificate. 
 The Pfizer/BioNTech vaccine is the first COVID-19 vaccine approved for children aged 12 to 
15 in the EU. 
1st June 2021  EU Gateway (interconnection of national systems) goes live, as part of the EU’s Digital 
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Chief Medical Officer (Department of Health) 
DOH 
 
Department of Health 
EMA 
 
European Medicines Agency 
HPRA 
 
Health Products Regulatory Authority[1] 
HSE 
 
Health Service Executive[2] 
NIAC 
 


























[1] HPRA: The Health Products Regulatory Authority is a state agency to protect and enhance public and animal health 
by regulating medicines, medical devices, and other health products, and monitoring the safety of cosmetics. 
(https://www.hpra.ie/)  
[2] HSE: The Health Service Executive is the publicly funded healthcare system in the Republic of Ireland, responsible 
for the provision of health and personal social services. (https://www.hse.ie/eng/)  
[3] NIAC: The National Immunisation Advisory Committee was established in 1998 by the Royal College of Surgeons 
Ireland. It is an independent expert group with membership from immunisation from a range of healthcare 
professional bodies that provides evidence-based advice to the Chief Medical Officer and the Department of Health on 
vaccines, immunisation, and related health matters to inform health policies in Ireland. (https://www.rcpi.ie/policy-
and-advocacy/national-immunisation-advisory-committee/) 
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APPENDIX C  
 
PRIORITY GROUPS AND COVID-19 VACCINATION IN THE UK  
 
Please note: The Joint Committee on Vaccination and Immunisation (JCVI) identified priority groups for 




The UK’s devolved administrations have implemented their own COVID-19 vaccination rollout programmes 
on a phased basis. For example: Wales, COVID-19 Vaccine Priority Groups https://gov.wales/covid-19-
vaccine-priority-groups; Scotland, COVID-19 Vaccination Programme Priority List 
https://www.gov.scot/publications/foi-202100144309/; and Northern Ireland, COVID-19 Vaccination 
Programme Phased Plan http://www.health-ni.gov.uk/publications/covid-19-vaccination-programme-
phased-plan, which is set out below by way of example. 
 
 
Priority Risk group  Phase Timeline  
1 Older adults resident in a care home and care home 
workers (12k residents and 16K staff) 
 
Phase 1 Dec/Jan 2021 
2 All those 80 years of age and over (<72K) and health and 
social care (70K) and domestically care workers (<25K) 
 
Phase 1 Dec/Jan 2021 
3 All those 75 years of age not already vaccinated (<62K) 
 
Phase 2 Jan/Feb 2021 
4 All those 70 years of age not already vaccinated (<81K) 
and extremely clinically vulnerable (95K) and Carers. 
 
Phase 2 Jan/Feb 2021 
5 All those 65 years of age not already vaccinated (<90K) 
 
Phase 2 Jan/Feb 2021 
6 All individuals aged 16 years to 64 years with underlying 
health conditions which put them at higher risk of serious 
disease and mortality + the Carers 
 
Phase 2 Jan/Feb 2021 
7 All those 60+ years of age not already vaccinated (<106K) 
 
Phase 3 Mar/April 2021 
8 All those 55+ years of age not already vaccinated (<125K) 
 
Phase 3 Mar/April 2021 
9 All those 50+ years of age not already vaccinated (<132K) 
 
Phase 3 Mar/April 2021 
10 All those 40+ years of age not already vaccinated (<242k) 
 
Phase 4 Mar/April 2021 
11 All those 30+ years of age not already vaccinated (<251k) 
 
Phase 4 Apr/May 2021 
12 All those 18+ years of age not already vaccinated (<282k) 
 
Phase 4 Apr/May 2021 
13 Autumn/ Winter booster programme 2021 
 
Phase 5 Winter 2021 onwards 
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APPENDIX D 
 
PRIORITY GRUPS AND COVID-19 VACCINATION IN the REPUBLIC of IRELAND 
 
Priority  Priority group Rationale Phases141 Roll-out  
1 People aged ≥65 years who are residents of 
long-term care facilities (and healthcare 
workers/staff of these facilities) 
At greatest risk of severe 
illness and death. 
Initial Roll-Out 29 Dec 
2020 
2 Frontline healthcare workers (in direct patient 
contact roles, including vaccinators, or who risk 
exposure to bodily fluids or aerosols and those 
providing services essential to the vaccination 
programme) 
At very high or high risk of 
exposure and/or 
transmission. 
Initial Roll-Out 7 Jan 2021 
3 People aged 70 and older in the following 
order: ≥85 years; 80-84 years; 75-79 years; and 
70-74 years 
 
At higher risk of 





4 People aged 16-69 with a medical condition 
that puts them at very high risk of severe 
COVID-19 disease and death. 
At similar very high risk of 
hospitalisation & death as 
those aged 70-74. 
Initial Roll-Out  8 Mar 
2021 
5 All people aged 60-69 (including those at high 
risk)142 (65-69 ages initially, with ages 60-64 
initiating on 23rd April) 
 
At high-risk of 
hospitalisation & death 
Initial Roll-Out 15 Apr 
2021  
6 Other people aged 65-69 and key workers 
essential to the vaccine programme143 
At high-risk of 
hospitalisation & death. 
Initial Roll-Out No data 
7 People aged 16-59 years with medical 
conditions.144 
At high risk of severe 
COVID-19 disease 
Initial Roll-Out No data 
8 Residents of long-term care facilities aged 16-
64145 
High risk of transmission Initial Roll-Out No data 
9 People aged 50-59 years146  Mass Ramp-Up No data 
 
                                                 
EXPLANATORY NOTES 
141 The three phases were outlined in the National COVID-19 Vaccination Programme: Strategy. The three phases are (i) Initial 
Roll-Out (for limited number of doses); (ii) Mass Ramp-up; (iii) Open Access. The population to be vaccinated for each of these 
phases would be determined ‘per Government-approved population sequencing’. The Initial Roll-Out phase vaccination sites 
were listed as long-term care facilities and large-scale healthcare sites which coincides with the focus on the highest priority 
groups identified being in these settings. The latter phases would initiate following large numbers of doses being available with 
primarily have mass vaccination centres and GPs and pharmacies used as vaccination sites. 
142 Under the original vaccine allocation strategy this cohort was ‘people aged 65-69 whose underlying condition puts them at 
a high risk of severe COVID-19 disease and death’ but following the change to an aged-based system, the cohort was amended.  
143 This group is no longer an active cohort as it was intended to be vaccinated simultaneously with cohort 5 and the two 
cohorts merged when the age-based system was introduced. 
144 Under the original vaccine allocation strategy this cohort was ‘people aged 16-64 who have an underlying condition that 
puts them at high risk of severe disease and death’ but changed following the introduction to an age-based system. 
145 This is no longer an active cohort due to the changes to an age-based system, people in this cohort are now being vaccinated 
according to age. 
146 Under the original vaccine allocation strategy this cohort was ‘people aged 16-64 living or working in crowded settings, and 
in parallel, people aged 64 years and younger’ but was changed following the introduction to an age-based system. There is no 
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RATES OF COVID-19 VACCINATION IN THE UK AND IRELAND  
 







(9 May 2021) 
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38.6% England 
10.3% RoI  
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